Oppenheimer analyst Jay Olson maintained a Buy rating on Sierra Oncology (SRRA) today and set a price target of $29.00. The company’s shares closed last Monday at $18.32.
According to TipRanks.com, Olson is a 4-star analyst with an average return of 11.5% and a 50.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Madrigal Pharmaceuticals, and Enanta Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sierra Oncology with a $34.67 average price target, implying an 87.3% upside from current levels. In a report issued on June 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $29.00 price target.
See today’s analyst top recommended stocks >>
Sierra Oncology’s market cap is currently $226.9M and has a P/E ratio of -2.90. The company has a Price to Book ratio of 2.23.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of patients with cancer. It engages in the business of researching, developing, and commercializing therapies for the treatment of patients with cancer. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.
